Open Beta
TREN
MetriLume
TREN

US marketsXBIO

SEC-sourced researchBeta

XBIO

Xenetic Biosciences, Inc.

Company comparison ↗

Data passport

CIK
0001534525
Exchange
Nasdaq
Business activity
— · SIC 2834
Financial inputs
6/6
Filing date
Sep 23, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2024: 2,500,284.0000 USD; December 2025: 2,976,411.0000 USD3M USD0 USD0December 2024December 2025
XBIO · Exact amounts and source periods · USD
Period endRevenueFiling date
December 20242,500,284.0000Mar 12, 2026
December 20252,976,411.0000Mar 12, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 20252,976,411.0000-2,680,860.0000-2,286,651.00008,363,847.0000968,025.0000Mar 12, 2026
December 20242,500,284.0000-3,960,275.0000-2,817,478.00006,901,443.0000894,263.0000Mar 12, 2026

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenues$2.98MDecember 2025Mar 12, 202610-K
Previous period revenueRevenues$2.5MDecember 2024Mar 12, 202610-K
Net incomeNetIncomeLoss-$2.68MDecember 2025Mar 12, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$2.29MDecember 2025Mar 12, 202610-K
Total assetsAssets$8.36MDecember 2025Mar 12, 202610-K
Total liabilitiesLiabilities$968.03KDecember 2025Mar 12, 202610-K

New filings

Explore methodology ↗